Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vupanorsen in Homozygous Familial Hypercholesterolemia
NCT03455777Phase 2Withdrawn
- Sponsor
- Akcea Therapeutics
- Start
- Apr 2018
- Primary completion
- Sep 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vupanorsen in homozygous familial hypercholesterolemia (HoFH), sponsored by Akcea Therapeutics. Primary endpoint: Reduction of low density lipoprotein cholesterol at 14 weeks. Planned start Apr 2018; status: withdrawn.
02
Drugs
vupanorsen
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT03455777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455777.